ARTIVA BIOTHERAPEUTICS INC (ARTV) Stock Price, Forecast & Analysis
USA - NASDAQ:ARTV - US04317A1079 - Common Stock
ARTV Key Statistics, Chart & Performance
The current stock price of ARTV is 3.46 USD. In the past month the price increased by 23.13%. In the past year, price decreased by -73.61%.
ARTV Latest News, Press Relases and Analysis
ARTV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About ARTV
Company Profile
Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. The company is headquartered in San Diego, California and currently employs 105 full-time employees. The company went IPO on 2024-07-19. The firm is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Company Info
ARTIVA BIOTHERAPEUTICS INC
5505 Morehouse Drive
San Diego CALIFORNIA US
Employees: 105
Phone: 18582674467
ARTIVA BIOTHERAPEUTICS INC / ARTV FAQ
What does ARTIVA BIOTHERAPEUTICS INC do?
Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. The company is headquartered in San Diego, California and currently employs 105 full-time employees. The company went IPO on 2024-07-19. The firm is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
What is the stock price of ARTIVA BIOTHERAPEUTICS INC today?
The current stock price of ARTV is 3.46 USD. The price increased by 0.58% in the last trading session.
Does ARTIVA BIOTHERAPEUTICS INC pay dividends?
ARTV does not pay a dividend.
What is the ChartMill technical and fundamental rating of ARTV stock?
ARTV has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is ARTV stock listed?
ARTV stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of ARTV stock?
ARTIVA BIOTHERAPEUTICS INC (ARTV) operates in the Health Care sector and the Biotechnology industry.
Can you provide the upcoming earnings date for ARTIVA BIOTHERAPEUTICS INC?
ARTIVA BIOTHERAPEUTICS INC (ARTV) will report earnings on 2025-11-18.
ARTV Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ARTV. When comparing the yearly performance of all stocks, ARTV is a bad performer in the overall market: 87.79% of all stocks are doing better.
ARTV Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARTV. No worries on liquidiy or solvency for ARTV as it has an excellent financial health rating, but there are worries on the profitability.
ARTV Financial Highlights
Over the last trailing twelve months ARTV reported a non-GAAP Earnings per Share(EPS) of -3.28. The EPS decreased by -370.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.08% | ||
| ROE | -50.09% | ||
| Debt/Equity | 0 |
ARTV Forecast & Estimates
12 analysts have analysed ARTV and the average price target is 16.73 USD. This implies a price increase of 383.47% is expected in the next year compared to the current price of 3.46.
For the next year, analysts expect an EPS growth of 34.13% and a revenue growth -100% for ARTV